Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Diana S. Rosman"'
Autor:
Boris Pasche, Albert de la Chapelle, Antonio Di Cristofano, Laura Valle, Chiang-Ching Huang, Guang-Yu Yang, Jie Liao, Michael Pennison, Diana S. Rosman, Maureen Sadim, Yanfei Xu, Sharbani Phukan, Qinghua Zeng
Supplementary Figure 1 from Tgfbr1 Haploinsufficiency Is a Potent Modifier of Colorectal Cancer Development
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94f4a33d39d4ae12c565bf358646241d
https://doi.org/10.1158/0008-5472.22377507.v1
https://doi.org/10.1158/0008-5472.22377507.v1
Autor:
Jennifer E. Bruin, Nelly Saber, Natalie Braun, Jessica K. Fox, Majid Mojibian, Ali Asadi, Campbell Drohan, Shannon O’Dwyer, Diana S. Rosman-Balzer, Victoria A. Swiss, Alireza Rezania, Timothy J. Kieffer
Publikováno v:
Stem Cell Reports, Vol 4, Iss 4, Pp 605-620 (2015)
Human embryonic stem cell (hESC)-derived pancreatic progenitor cells effectively reverse hyperglycemia in rodent models of type 1 diabetes, but their capacity to treat type 2 diabetes has not been reported. An immunodeficient model of type 2 diabetes
Externí odkaz:
https://doaj.org/article/054c9233aa8a42bb87c0b24cb06eb7b0
Autor:
Victoria A. Swiss, Ali Asadi, Jessica K. Fox, Shannon O'Dwyer, Campbell Drohan, Majid Mojibian, Jennifer E. Bruin, Timothy J. Kieffer, Natalie Braun, Alireza Rezania, Nelly Saber, Diana S. Rosman-Balzer
Publikováno v:
Stem Cell Reports
Stem Cell Reports, Vol 4, Iss 4, Pp 605-620 (2015)
Stem Cell Reports, Vol 4, Iss 4, Pp 605-620 (2015)
Summary Human embryonic stem cell (hESC)-derived pancreatic progenitor cells effectively reverse hyperglycemia in rodent models of type 1 diabetes, but their capacity to treat type 2 diabetes has not been reported. An immunodeficient model of type 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7cf7eb1f62fa474a1e64346e1c0d53af
http://europepmc.org/articles/PMC4400611
http://europepmc.org/articles/PMC4400611
TGFBR1*6A is a common hypomorphic variant of the type 1 transforming growth factor β receptor (TGFBR1), which has been associated with increased cancer risk in some studies. Although TGFBR1*6A is capable of switching TGF-β growth-inhibitory signals
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a0b4960e261ea0ebbbbefd3ebc7a84d
https://europepmc.org/articles/PMC2673101/
https://europepmc.org/articles/PMC2673101/
The combined observation that 20-30% of all patients with breast cancer have a family history of the disease and the results from twin studies showing that 25% of breast cancer cases are heritable, indicate that this malignancy is one of the most com
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d87dd272c170416988da1473ca48e5f7
https://europepmc.org/articles/PMC2670199/
https://europepmc.org/articles/PMC2670199/
Autor:
Trenton R. Schoeb, Lakisha Moore-Smith, Jacquelyn W. Zimmerman, Andra R. Frost, Ming Zhang, Boris Pasche, Diana S. Rosman-Balzer, Michael J. Pennison, Peter M. Siegel
Publikováno v:
Cancer Research. 73:1406-1406
Background: We previously identified a hypomorphic TGF-β type 1 receptor variant (TGFBR1*6A) that is associated with cancer risk and has impaired TGF-β signaling capability. Two recent large meta-analyses of case control studies have found a signif
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e2ce58de0cb5c72e5ca8054e112eb0e0
https://doi.org/10.1158/1538-7445.am2013-1406
https://doi.org/10.1158/1538-7445.am2013-1406
Autor:
Kenneth Offit, Yu Chen, Carole Oddoux, Lisa Baddi, Helen Huang, Diana S. Rosman, Loren S. Michel, Sharbani Phukan, Virginia G. Kaklamani, Habibul Ahsan, Junjian Liu, Ciarán Bradley, Boris Pasche, Alfred Rademaker, Harry Ostrer, Bree McDaniel, Chris Hegarty
Publikováno v:
Cancer research. 65(8)
There is growing evidence that common variants of the transforming growth factor-β (TGF-β) signaling pathway may modify breast cancer risk. In vitro studies have shown that some variants increase TGF-β signaling, whereas others have an opposite ef
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc8cc27e6d4e5eb9d78335a5e489f53e
https://pubmed.ncbi.nlm.nih.gov/15833881
https://pubmed.ncbi.nlm.nih.gov/15833881
Publikováno v:
Cancer Research. 71:2118-2118
Transforming Growth Factor-β (TGF-β) inhibits cell growth and drives of epithelial-to-mesenchymal transition, invasion and migration. Somatic mutations in the TGFBR1 and -2 genes have been found in cancer (n=9), while germline mutations are the pro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dc99f93a45de30030ae8bc938c2fb729
https://doi.org/10.1158/1538-7445.am2011-2118
https://doi.org/10.1158/1538-7445.am2011-2118
Autor:
Riccardo Fodde, M. Eileen Dolan, Wendy L. Frankel, Heather Hampel, Yansong Bian, Everett E. Vokes, David E. Schuller, Gunnar von Heijne, Jas C. Lang, Thomas J. Knobloch, Farida Siddiqui, Albert de la Chapelle, William S. Lane, IngMarie Nilsson, Christopher M. Weghorst, Boris Pasche, Trinidad Caldés, Amit Agrawal, Vundavalli V. Murty, Lisa Baddi, Junjian Liu, Sharbani Phukan, Virginia G. Kaklamani, Antonio Di Cristofano, Thomas W. Prior, Diana S. Rosman, Chiang Ching Huang
Publikováno v:
JAMA. 294:1634
ContextTGFBR1*6A is a common polymorphism of the type I transforming growth factor β receptor (TGFBR1). Epidemiological studies suggest that TGFBR1*6A may act as a tumor susceptibility allele. How TGFBR1*6A contributes to cancer development is large
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c44d5053e20a69a9b47bc45df284b040
https://doi.org/10.1001/jama.294.13.1634
https://doi.org/10.1001/jama.294.13.1634
Autor:
Boris Pasche, Diana S. Rosman, Yiansong Bian, Junjian Liu, Virginia G. Kaklamani, Christopher M. Weghorst, A de la Chapelle, Thomas J. Knobloch, Lisa Baddi
Publikováno v:
Journal of Clinical Oncology. 23:9511-9511
9511 Background: TGFBR1*6A is a common variant of the type I Transforming Growth Factor Beta receptor (TGFBR1). Epidemiological studies suggest that TGFBR1*6A may act as a common tumor susceptibili...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f41c6fe5f3c441dcff08012df7303790
https://doi.org/10.1200/jco.2005.23.16_suppl.9511
https://doi.org/10.1200/jco.2005.23.16_suppl.9511